Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-12 (withdrawn)

Claim 13. (currently amended) An aqueous pharmaceutical composition comprising an antibody at a concentration between about 20 and about 130 mg/ml, a polyol, a surfactant, and a buffer system comprising at least one buffer selected from the group consisting of citrate and ~~/or~~ phosphate, with a pH of about 4 to about 8, in amounts sufficient to formulate ~~an~~the antibody for therapeutic use ~~at a concentration of greater than about 45 mg/ml~~.

Claim 14. (original) The composition of claim 13, wherein the polyol is mannitol and the surfactant is polysorbate 80.

Claim 15. (currently amended) The composition of claim 14, which contains ~~5-20~~ about 5 to about 20 mg/ml of mannitol and ~~0.1-10~~ about 0.1 to about 10 mg/ml of polysorbate 80.

Claim 16. (currently amended) The formulation of claim 13, which contains an antibody, or antigen-binding portion thereof, which binds human tumor necrosis factor alpha (TNFα) and is the antibody D2E7 or an antigen binding portion thereof.

Claim 17. (currently amended) A liquid aqueous pharmaceutical formulation comprising

(a) ~~1-150~~ about 2 to about 150 mg/ml of antibody,

(b) ~~5-20~~ about 5 to about 20 mg/ml of mannitol,

(c) ~~0.1-10 mg/ml of Tween-800~~about 0 to about 15 mg/ml of polysorbate 80, and

(d) a buffer system comprising at least on buffer selected from the group consisting of citrate and ~~/or~~ phosphate, with a pH of about 4 to about 8.

Claim 18. (currently amended) The formulation of claim 17, wherein the pH is selected from the group consisting of between about 4.5 ~~to~~and about 6.0, between about 4.8 ~~to~~and about 5.5, and between about 5.0 ~~to~~and about 5.2.

Claim 19. (currently amended) The liquid aqueous pharmaceutical formulation of claim 17, which contains

(a) about 50 mg/ml of antibody,
(b) about 12 mg/ml of mannitol,
(c) about 1 mg/ml of ~~Tween 80~~polysorbate 80, and
(d) a buffer system comprising at least on buffer selected from the group consisting of citrate and~~/or~~ phosphate with a pH of about 4 to about 8.

Claim 20. (original) The formulation of claim 17, wherein the buffer system comprises

(a) about 1.3 mg/ml of citric acid,
(b) about 0.3 mg/ml of sodium citrate,
(c) about 1.5 mg/ml of disodium phosphate dihydrate,
(d) about 0.9 mg/ml of sodium dihydrogen phosphate dihydrate, and
(e) about 6.2 mg/ml of sodium chloride.

Claim 21. (currently amended) The formulation of claim 19, wherein the antibody is directed to tumor necrosis factor alpha (TNFα).

Claim 22. (currently amended) The formulation of claim 19, wherein the antibody, or antigen-binding portion thereof, binds human tumor necrosis factor alpha (TNFα) and is the antibody D2E7 or an antigen binding portion thereof.

Claim 23. (currently amended) The formulation of claim 22, which is administered to a subject suffering from a disorder in which tumor necrosis factor alpha (TNFα) activity is detrimental such that TNFα activity in the subject is inhibited.

Claim 24. (new) The liquid aqueous pharmaceutical formulation of claim 17, which contains

(a) about 50 mg/ml of antibody,

(b) about 12 mg/ml of mannitol, and

(c) about 1 mg/ml of polysorbate 80.

Claims 25. (new) A stable pharmaceutical formulation comprising Adalimumab at a concentration of between about 2 and about 150 mg/mL, wherein said formulation has a pH of about 4 to about 8.